Dynavax fought to win FDA approval for its hepatitis B vaccine, but now that it has a marketing license, the biotech's work is only just beginning.
Here is some other vaccine news of note for the week.
An investment fund formed by J.P. Morgan and the Gates Foundation, Global Health Investment Fund led Themis' €10 million series C.
Moderna unveiled two phase 1 prophylactic vaccine programs and a new Chikungunya antibody candidate at JPM.
Following mass immunization program halt, Dengvaxia’s marketing authorization in the Philippines has been put on hold for a year.
Not long after its acquisition by Sanofi, Protein Sciences is bidding adieu to its former leader.
Here's some other vaccine news of note for the week.
China's ApolloBio increased upfront payment, while also terminating its right to buy into Inovio.
Seqirus' adjuvanted flu vaccine Fluad is finally set for routine use in the U.K. because the current shot isn't working for the elderly.
Sanofi's recent loss in C. diff is a win for Pfizer and Valneva, which boast their own late-stage candidates, according to GlobalData.